DPA
TEVA icon

Delphi Private Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Delphi Private Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$5K – 90
2017
Q2 		$5K Buy
+100
New +$3.1K 0.01% 100
2016
Q3 		– Sell
-100
Closed -$5K – 541
2016
Q2 		$5K Hold
100
– – 0.01% 189
2016
Q1 		$5K Hold
100
– – 0.01% 189
2015
Q4 		$7K Buy
+100
New +$6.18K 0.01% 182

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Delphi Private Advisors's TEVA Position: Q3 2017 in Review

Delphi Private Advisors sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2017, closing a stake of 100 shares — an estimated $5K sold.

Delphi Private Advisors first reported a position in TEVA in Q4 2015 and held it in 4 quarters. The position peaked at $7K in Q4 2015. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Delphi Private Advisors reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2017 after selling out during the quarter.
  • Delphi Private Advisors sold 100 Teva Pharmaceutical Industries Limited shares in Q3 2017, an estimated $5K.
  • Delphi Private Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q4 2015 and held it in 4 quarters.
  • Delphi Private Advisors's Teva Pharmaceutical Industries Limited position peaked at $7K in Q4 2015.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2017.

Based on Delphi Private Advisors's 13F filing for Q3 2017, filed 16 Oct 2017.